KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
Clinical trial NCT06342960 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06342960
- Sponsor
- Kyverna Therapeutics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-01
- Primary completion
- 2028-10-01
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.